Connie N Hess1, Robert M Clare2, Megan L Neely2, Pierluigi Tricoci3, Kenneth W Mahaffey4, Stefan K James5, John H Alexander3, Claes Held5, Renato D Lopes3, Keith A A Fox6, Harvey D White7, Lars Wallentin5, Paul W Armstrong8, Robert A Harrington4, Erik Magnus Ohman3, Matthew T Roe9. 1. Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO. 2. Duke Clinical Research Institute, Durham, NC. 3. Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC. 4. Department of Medicine, Stanford University, Stanford, CA. 5. Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden; Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden. 6. British Heart Foundation Centre for Cardiovascular Sciences, University of Edinburgh, Edinburgh, Scotland, United Kingdom. 7. Auckland City Hospital, Green Lane Cardiovascular Service, Auckland, New Zealand. 8. Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. 9. Duke Clinical Research Institute, Durham, NC; Division of Cardiology, Department of Medicine, Duke University School of Medicine, Durham, NC. Electronic address: matthew.roe@dm.duke.edu.
Abstract
OBJECTIVE: Acute coronary syndrome (ACS) trials typically use a composite primary outcome (myocardial infarction [MI], stroke, or cardiovascular death), but differential patient characteristics, timing, and consequences associated with individual component end points as first events have not been well studied. We compared patient characteristics and prognostic significance associated with first cardiovascular events in the post-ACS setting for initially stabilized patients. METHODS: We combined patient-level data from 4 trials of post-ACS antithrombotic therapies (PLATO, APPRAISE-2, TRACER, and TRILOGY ACS) to characterize the timing of and characteristics associated with first cardiovascular events (MI, stroke, or cardiovascular death). Landmark analysis at 7 days after index ACS presentation was used to focus on spontaneous, postdischarge events that were not confounded by in-hospital procedural complications. Using a competing risk framework, we tested for differential associations between prespecified covariates and the occurrence of nonfatal stroke vs MI as the first event, and we examined subsequent events after the first nonfatal event. RESULTS: Among 46,694 patients with a median follow-up of 358 (25th, 75th percentiles 262, 486) days, a first ischemic event occurred in 4,307 patients (9.2%) as follows: MI in 5.8% (n = 2,690), stroke in 1.0% (n = 477), and cardiovascular death in 2.4% (n = 1,140). Older age, prior stroke/transient ischemic attack, prior atrial fibrillation, and higher diastolic blood pressure were associated with a significantly greater risk of stroke vs MI, whereas prior percutaneous coronary intervention was associated with a greater risk of MI vs stroke. Second events occurred in 32% of those with a first nonfatal stroke at a median of 13 (3, 59) days after the first event and in 32% of those with a first nonfatal MI at a median of 35 (5, 137) days after the first event. The most common second event was a recurrent MI among those with MI as the first event and cardiovascular death among those with stroke as the first event. CONCLUSIONS: Approximately 9% of patients experienced a first cardiovascular event in the post-ACS setting during a median follow-up of 1 year. Although the profile and prognostic implications of stroke vs MI as the first nonfatal event differ substantially, approximately one-third of these patients experienced a second event, typically soon after the first event. These findings have implications for improving post-ACS care and influencing the design of future cardiovascular trials.
OBJECTIVE: Acute coronary syndrome (ACS) trials typically use a composite primary outcome (myocardial infarction [MI], stroke, or cardiovascular death), but differential patient characteristics, timing, and consequences associated with individual component end points as first events have not been well studied. We compared patient characteristics and prognostic significance associated with first cardiovascular events in the post-ACS setting for initially stabilized patients. METHODS: We combined patient-level data from 4 trials of post-ACS antithrombotic therapies (PLATO, APPRAISE-2, TRACER, and TRILOGY ACS) to characterize the timing of and characteristics associated with first cardiovascular events (MI, stroke, or cardiovascular death). Landmark analysis at 7 days after index ACS presentation was used to focus on spontaneous, postdischarge events that were not confounded by in-hospital procedural complications. Using a competing risk framework, we tested for differential associations between prespecified covariates and the occurrence of nonfatal stroke vs MI as the first event, and we examined subsequent events after the first nonfatal event. RESULTS: Among 46,694 patients with a median follow-up of 358 (25th, 75th percentiles 262, 486) days, a first ischemic event occurred in 4,307 patients (9.2%) as follows: MI in 5.8% (n = 2,690), stroke in 1.0% (n = 477), and cardiovascular death in 2.4% (n = 1,140). Older age, prior stroke/transient ischemic attack, prior atrial fibrillation, and higher diastolic blood pressure were associated with a significantly greater risk of stroke vs MI, whereas prior percutaneous coronary intervention was associated with a greater risk of MI vs stroke. Second events occurred in 32% of those with a first nonfatal stroke at a median of 13 (3, 59) days after the first event and in 32% of those with a first nonfatal MI at a median of 35 (5, 137) days after the first event. The most common second event was a recurrent MI among those with MI as the first event and cardiovascular death among those with stroke as the first event. CONCLUSIONS: Approximately 9% of patients experienced a first cardiovascular event in the post-ACS setting during a median follow-up of 1 year. Although the profile and prognostic implications of stroke vs MI as the first nonfatal event differ substantially, approximately one-third of these patients experienced a second event, typically soon after the first event. These findings have implications for improving post-ACS care and influencing the design of future cardiovascular trials.
Authors: Matthew A Cavender; William B White; Yuyin Liu; Joseph M Massaro; Richard M Bergenstal; Cyrus R Mehta; Faiez Zannad; Simon Heller; William C Cushman; Christopher P Cannon Journal: Clin Cardiol Date: 2018-08-16 Impact factor: 2.882
Authors: Suying Li; Yi Peng; Xinyue Wang; Yi Qian; Pin Xiang; Sally W Wade; Haifeng Guo; J Antonio G Lopez; Charles A Herzog; Yehuda Handelsman Journal: Clin Cardiol Date: 2019-02-25 Impact factor: 2.882
Authors: Fadia Tohme Shaya; Krystal Sing; Robert Milam; Fasahath Husain; Michael A Del Aguila; Miraj Y Patel Journal: Am J Cardiovasc Drugs Date: 2020-06 Impact factor: 3.571
Authors: Erin S Mackinnon; Ron Goeree; Shaun G Goodman; Raina M Rogoza; Millicent Packalen; Louisa Pericleous; Ponda Motsepe-Ditshego; Paul Oh Journal: CJC Open Date: 2021-10-20
Authors: Iiro Toppila; Liisa Ukkola-Vuoti; Julia Perttilä; Outi Törnwall; Juha Sinisalo; Juha Hartikainen; Seppo Lehto Journal: Clin Cardiol Date: 2022-03-15 Impact factor: 3.287